

USD Global Health Fund

An investment fund option for variable life insurance products of **The Manufacturers Life Insurance Co., (Phils), Inc.**

Investment Objective

The Fund aims to maximize total return by investing substantially all of its assets in one or more collective investment schemes which aims to provide medium to long term capital growth by investing mainly in equity and equity-related securities in health care and related industries globally, which are listed on any stock exchange. The Target Fund may invest in companies which derive a significant portion of their earnings from medical and pharmaceutical products and services. The remaining assets may include bonds and deposits.

Fund Information

Inception Date May 2022	Fund Size USD 116.59 thousand	Fund Currency US dollar	Dealing/Valuation Daily
Price (NAV/unit) USD 0.979	Management Fee 2.25% per annum	Bloomberg Ticker PHEQUUH	

Performance Return (June 30, 2022)

USD Global Health Fund (net of management fee)	1 Month	YTD	1 Year	3 Years	5 Years	Since Inception
Absolute	-2.39%	n.a.	n.a.	n.a.	n.a.	-2.10%
Annualized	n.a.	n.a.	n.a.	n.a.	n.a.	-2.10%

Past performance is not an indication of future results. Information about the portfolio's holdings, asset allocation, or country diversification is historical and is not an indication of future portfolio composition, which will vary.

Monthly Net Asset Value per Unit

Information will be provided once available

Top Five Holdings


Eli Lilly and Company	7.68%
UnitedHealth Group Incorporated	7.62%
Pfizer Inc.	6.91%
Johnson & Johnson	5.94%
Thermo Fisher Scientific Inc.	5.22%

Monthly Performance

Information will be provided once available

Portfolio Breakdown

Asset Allocation (at Market Value)



■ Manulife Global Fund - Healthcare Fund 100.00%

USD Global Health Fund

Market Review

The global equity markets moved sharply lower in June, continuing the downtrend that started in late 2021. The majority of the news flows were negative, with weakening economic indicators, stubbornly higher inflation, and tighter central bank policies combining to raise the odds that the world economy will enter a period of stagflation. Further, investors began to anticipate that recent events would translate to lower corporate profits in the upcoming reporting season. Geopolitical issues remained an additional headwind, with the ongoing conflict in Ukraine raising concerns about the reliability of Europe's energy supplies.

In contrast to the first five months of the year, energy and other commodity-related stocks lost ground and failed to offset the continued weakness in growth stocks. On the positive side, China began to ease its stringent Covid-19 lockdown policies. The nation's market rose as the economic outlook improved, allowing it to finish the month as one of the few major countries with a gain.

The healthcare sector declined during the period, although it significantly outperformed global markets, as measured by the MSCI World Index. It provided relative protection in the negative market environment and was the best performing sector for the month. The healthcare equipment & supplies and life science tools & services sub-sectors underperformed relative to the overall sector. Healthcare technology and biotechnology companies provided positive returns in the tough environment and outperformed relative to the overall sector.

Outlook

We believe select companies within the healthcare sector offer the potential for strong long-term outperformance. We continue to deploy our bottom-up fundamental investment process informed by assessment of emerging scientific and medical trends coupled with our intrinsic valuation analysis. This process should continue to ensure that our allocation of capital to companies tackling important unmet medical needs drives portfolio construction with deference to appropriate valuation discipline.

We continue to monitor the Covid-19 pandemic globally and have positioned the portfolio consistent with our conclusions. As such, within the biopharmaceuticals sub-sector, we are focused on companies with best-in-class product portfolios serving patients in disease states with inelastic demand (cancer, diabetes, etc.). In addition, we have selectively rounded up positions with direct exposure to Covid-19 therapeutics and vaccines, consistent with our continued thesis that the pandemic/endemic will persist for several more quarters if not years. We also continue to monitor potential volatility given possible US drug pricing actions corresponding with ongoing congressional legislative initiatives. These pricing actions may appear less likely given earlier developments in Washington but warrant our continued scrutiny.

Fundamentals within specific pockets of both the healthcare equipment & supplies and life science tools & services industries remain attractive, although valuations remain somewhat stretched. Specifically, select established leaders in the Covid-19 diagnostics space offer a unique investment opportunity as we believe the durability of these businesses is currently being underappreciated by the market. In addition, we expect certain companies to experience disproportionate disruptions as a result of the ongoing Covid-19 pandemic and have reduced our exposures accordingly.

Within the healthcare providers & services industry, we see value in select supply chain companies, specifically pharmaceutical wholesalers. We expect these companies to see improving margins from accelerating drug inflation and continued recovery in prescription volumes. We have also increased our positioning in select healthcare insurers commensurate with improved profit profiles associated with the Covid-19 induced reduction in office visits and surgeries in the Medicare population.

Mergers and acquisitions activity in the healthcare sector appears to be increasing as we enter the later stages of a multi-year capital markets financing window, and we expect the historic run of initial public offerings and secondary offerings to continue to wane over time. We believe the Fund is well-positioned in this regard.

Notwithstanding aforementioned headline risks, we believe that the defensive characteristics of the sector coupled with strong organic growth in select companies should provide strong outperformance over a full market cycle.

The investment fund option for The Manufacturers Life Insurance Company's variable life insurance product is managed by Manulife Investment Management and Trust Corporation.

The Fund mentioned in this document is specific to variable life insurance contracts and is not considered a mutual fund. Yields depend on interest and foreign exchange rate levels, both of which may fluctuate. Other factors that affect yield include changes in the credit standing of the issuers and changes in the value of the stocks and dividends received. Further, investments of the Fund may provide that their values be determined based on prices or yields of other securities, instruments or foreign currencies, and such provisions may result in negative fluctuations in the value of these investments and, in turn, the Fund's yields. Thus, the performance of the separate account(s) is not guaranteed and the value of the policy could be less than the capital invested. THE VARIABLE LIFE POLICYHOLDER SHALL BEAR ALL INVESTMENT RISKS. Past performance of the Fund is not necessarily indicative of future performance. Yields are not guaranteed.

The information and/or analysis contained in this material have been compiled or arrived at from sources believed to be reliable but The Manufacturers Life Insurance Company ("Manulife Philippines") does not make any representation as to their accuracy, correctness, usefulness or completeness and does not accept liability for any loss arising from the use hereof or the information and/or analysis contained herein. Information about the portfolio's holdings, asset allocation, or country diversification is historical and is not an indication of future portfolio composition, which will vary. Neither Manulife Philippines or its affiliates, nor any of their directors, officers or employees shall assume any liability or responsibility for any direct or indirect loss or damage or any other consequence of any person acting or not acting in reliance on the information contained herein.

The information in this material may contain projections or other forward-looking statements regarding future events, targets, management discipline or other expectations, and is only as current as of the date indicated. There is no assurance that such events will occur, and may be significantly different than that shown here. The information in this material including statements concerning financial market trends, are based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. This material was prepared solely for informational purposes and does not constitute a recommendation, professional advice, an offer, solicitation or an invitation by or on behalf of Manulife Philippines to any person to buy or sell any security. This material should not be viewed as a current or past recommendation or a solicitation of an offer to buy or sell any investment products or to adopt any investment strategy. Nothing in this material constitutes investment, legal, accounting or tax advice, or a representation that any investment or strategy is suitable or appropriate to your individual circumstances, or otherwise constitutes a personal recommendation to you. Past performance is not an indication of future results.

Manulife and the block design are registered service marks and trademarks of The Manufacturers Life Insurance Company and used by it and its affiliates including Manulife Financial Corporation.